We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Cell and Tissue Acquisition Device Improves Efficiency at More Affordable Price

By LabMedica International staff writers
Posted on 26 Feb 2013
An innovative and affordable new cell and tissue acquisition instrument improves efficiency and ease-of-use compared to existing laser-assisted microdissection systems.

Kuiqpick, introduced by NeuroInDx, Inc. More...
(Los Angeles, CA, USA), is the innovative new laser-assisted microdissection and acquisition system for research laboratories. It includes the additional the capacity to collect cells from tissues and cultures without affecting their viability, enabling the collected cells to then be cultured for further analysis and downstream applications. Also notable, Kuiqpick costs less than USD 30,000 per device, about one-fourth the cost of existing systems. “Kuiqpick [opens] the door for more labs to conduct the critical collection of live cells and tissue areas for examination and culturing,” said Stan Karsten, PhD, NeuroInDx chief scientific officer and cofounder; “For too long, the high cost of tissue microdissection and cell sorting technologies have limited cell-specific research. With the introduction of Kuiqpick, more labs and researchers can afford the technology.”

Rebecca Stockton, PhD, a University of California, Los Angeles (UCLA) assistant professor of pediatrics, uses Kuiqpick to study cerebral cavernous malformations and said, “[Kuiqpick is] perfect for collecting small abnormal blood vessels from the brain tissue and specific cells from cultures based on their form and structure, or their morphology, which is critical for my research.”

Originally conceived at UCLA and further developed by NeuroInDx, Kuiqpick can be attached to an inverted microscope to dissect brain tissue slices at the cellular resolution and collect individual cells from various cell cultures. A single press of a button initiates the collection of the brain tissue area or cells into a disposable capillary unit. Collected tissue samples are then transferred to a test tube for further use. “Kuiqpick is a novel and highly accurate system that has already proven to be extremely efficient in the isolation of specific cell populations from live and freshly frozen brain tissues,” said Dr. Lili C. Kudo, president and CEO of NeuroInDx; “It can be successfully used in a variety of molecular studies, including stem cell research, genomics and proteomics.”

NeuroInDx also offers to provide researchers with custom cell and tissue collection services and subsequent gene expression-microarray experiments, thus saving time and funding for their projects.

Related Links:

NeuroInDx





Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Steam Sterilizer
Hi Vac II Line
New
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The schematic diagram links key MASLD, MASH, and MASLD-HCC molecular drivers to emerging multi‑omics biomarkers and therapeutic modalities, highlighting the current barriers in clinical translation and strategic solutions aimed at refined risk stratification and personalized medicine (Photo courtesy of ©Science China Press)

Emerging Biomarkers Advance Early Detection of MASLD and Liver Cancer Risk

Metabolic dysfunction-associated steatotic liver disease (MASLD) affects about 30% of people worldwide and can advance to metabolic dysfunction-associated steatohepatitis (MASH), fibrosis, cirrhosis, and... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.